

# TITLE: NEW MOLECULE FOR AORTIC ABDOMINAL ANEURYSM (AAA) PREVENTION AND TREATMENT

## FIELD OF INTEREST

Biotechnology, Pharma (Cardiovascular, Renal)

## CLINICAL NEED

Abdominal Aortic Aneurysm (AAA) is potentially life-threatening. AAA consists of a dilation of the abdominal aorta of unknown etiology. Current therapies for AAA comprises acetylsalicylic acid (100 mg) and an inhibitor of hydroxymethylglutaryl CoA reductase (20 / 40mg) treatment once a day. If the patient has any additional risk factor, it should be applied the corresponding treatment: antihypertensives in case of treatment for arterial hypertension or diuretics, angiotensin-converting enzyme inhibitors, beta-blockers and, in some cases, potassium and digoxin in case of treatment for heart failure.

## DESCRIPTION OF THE INVENTION

Lipocalin-2 (Lcn2) is increased in the plasma of patients with AAA. It accumulates within the intraluminal thrombus of the aneurysm and is released into the extracellular medium.

The present invention uses a neutralizing molecule for Lipocalin-2 for preventing and treating damage caused by AAA.

## TECHNOLOGY KEYWORDS

Aortic Abdominal Aneurysm, Lipocalin-2, Vascular, Neutrophils, Extracellular Matrix Metalloproteinases, Elastin

## IPR STATUS

Patent application number: P201431737.

Applicants: IIS-FJD, UAM.

## TYPE AND ROLE OF PARTNER

Looking for technological partners for going through clinical trials as well as commercial partners interested in licensing.

---

## Contact details:

Innovation Unit  
e-mail: [irene.ruano@fjd.es](mailto:irene.ruano@fjd.es)  
Phone number: 0034-915504800 Ext.3455